Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
Geron is discontinuing the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis after its independent Data Monitoring Committee advised the trial was unlikely to meet its primary endpoint of overall survival. The trial enrolled 327 patients randomized 2:1 versus best available therapy; no new safety signals were observed and the known safety profile is unchanged. The company says it remains focused on growing RYTELO demand in the U.S. and expanding access for lower-risk MDS patients, where the drug is already approved in the U.S.
Key figures
- Drug Name
- imetelstat (RYTELO)
- Phase Of Trial
- Phase 3
- Endpoint
- overall survival
- Indication
- JAK inhibitor relapsed/refractory myelofibrosis
- Trial name
- IMpactMF
- Randomization
- 2:1 open-label controlled
- Patients enrolled
- 327
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.